TEVA - Teva Pharmaceutical Industries Limited
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 7.21 |
| Open | 7.26 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 21500 |
| Day's Range | 7.22 - 7.37 |
| 52 Week Range | 6.78 - 11.45 |
| Volume | |
| Avg. Volume | 12,610,652 |
| Market Cap | 8.225B |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.45 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 9.72 |
Fair Value
Related Research
Business WirePhil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
SAN FRANCISCO, June 06, 2023--Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva’s Digihaler system is the first and only smart inhaler system that can provide objective inhaler data to help patients and their doctors have informed treatment discussion in support of asthma manageme
Motley FoolTeva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?
On May 18, Teva Pharmaceuticals (NYSE: TEVA) announced that it was planning to execute a strategic pivot that would return the company to growth after a long period of stagnation. Between the upcoming fruits of its biosimilar generic medicines pipeline and its anticipated investments in expanding its pipeline assets, management is hoping to mark a turnaround point within the next few years and meet its financial targets for 2027. Generally, generic drug manufacturers are companies that enjoy stable demand for cheaper copies of critical medicines.
Business WireTeva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
TEL AVIV, Israel & PARSIPPANY, N.J., June 02, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023. Two presentations feature real-world data for AUSTEDO (deutetrabenazine) tablets for adults living with TD. Data presented will include interim findings from the START trial, a Phase 4 stud
Simply Wall St.Shareholders in Teva Pharmaceutical Industries (NYSE:TEVA) have lost 66%, as stock drops 6.3% this past week
Generally speaking long term investing is the way to go. But no-one is immune from buying too high. For example the...
Insider MonkeyAnalysts are Upgrading These 10 Stocks
In this article, we will take a look at the 10 stocks recently upgraded by analysts. If you want to see some more stocks on the list, go directly to Analysts are Upgrading These 5 Stocks. US stock markets are wavering as politicians continue their talks about the debt ceiling problem. The beginning of the week […]
ZacksZacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.
Zacks3 Generic Drug Stocks to Watch Amid Macro Headwinds
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Insider Monkey15 Stocks Warren Buffett Sold
In this article, we will discuss 15 stocks Warren Buffett sold. However, if you want to go straight to the top five stocks, you can look at the 5 Stocks Warren Buffett Sold. Berkshire Hathaway, headed by Warren Buffett, sold $13.3 billion worth of stock in the first quarter of 2023 while investing only a […]
Business WireTeva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
TEL AVIV, Israel & PARSIPPANY, N.J., May 20, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that four studies across its neuroscience portfolio will be presented during the American Psychiatric Association’s (APA) 2023 Annual Meeting taking place on May 20-24, 2023. Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for the tr
Barrons.comTeva to Slim Down Generic Drug Business in Turnaround Effort. The Stock Is Jumping.
Teva Pharmaceutical Industries one of the world’s largest generic drugmakers, said Thursday it will cut back on its core generic drugs business while focusing on its pipeline of new treatments. The new corporate strategy, Teva said, aims to deliver a “pivot to growth.” Teva (ticker: TEVA) earnings have dropped steadily over the past decade, to $2.52 per share in 2022 from $5.35 per share in 2013.
- Reuters
UPDATE 1-Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027
Teva Pharmaceutical Industries' drug Austedo should reach sales of $2.5 billion by 2027, Chief Executive Richard Francis said on Thursday. Austedo is Teva's branded treatment for Huntington's Disease but the drug also helps those with movement disorder tardive dyskenisa. Teva expects revenue from Austedo to reach $1.2 billion in 2023 from $971 million in 2022.
Motley FoolWhy Teva Pharmaceutical Stock Is Jumping Today
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were jumping 5.7% as of 11:21 a.m. ET on Thursday. Francis maintained that focusing on these four areas will enable Teva to "gain momentum as a stronger, bolder, and simpler organization." At least one Wall Street analyst seemed to be convinced that Teva could now be on the right track.
- Reuters
Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027
Teva Pharmaceutical Industries' drug Austedo should reach sales of $2.5 billion by 2027, chief executive Richard Francis said on Thursday. Austedo is Teva's branded treatment for Huntington's Disease but the drug helps those with the movement disorder tardive dyskenisa. Ahead of unveiling Teva's new strategy, Francis told reporters that only 15% of the 800,000 people suffering from tardive dyskenisa take medication.
- Business Wire
Teva Launches New "Pivot to Growth" Strategy
TEL AVIV, Israel, May 18, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO®, AJOVY®, UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business. These four pillars are expected to deliver enhanced value and create a greater impact
- Reuters
UPDATE 3-US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.
ReutersUS Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.
Business WireAUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
TEL AVIV, Israel & PARSIPPANY, N.J., May 15, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets are now available for adults in the United States in 6 mg, 12 mg and 24 mg tablet strengths. AUSTEDO XR was recently approved by the U.S. Food and Drug Administration (FDA) for adults living with tardive dyskinesia (TD) and chorea associated with Huntington’s d
ZacksTEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Investor's Business DailyTeva Undercuts Its 50-Day Line On Flat Sales As Profit Misses Forecasts
Teva Pharmaceutical reported lighter-than-expected earnings for the first quarter, leading Teva stock to plunge Wednesday.
Motley FoolTeva Pharmaceutical Industries (TEVA) Q1 2023 Earnings Call Transcript
Additional information regarding these statements and our non-GAAP financial measures is available on our earning release and in our SEC Forms 10-K and 10-Q. To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's Q1 2023 results and business performance, recent events, and priorities going forward. Joining Richard and Eli on the call today are Sven Dethlefs, Teva's head of North America business; and Dr. Eric Hughes, our head of R&D and chief medical officer.
ZacksCompared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Business WireTeva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
TEL AVIV, Israel, May 10, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023.
Insider Monkey20 Most Used Prescription Drugs In The US
In this article, we will take a look at the 20 most used prescription drugs in the US. If you don’t want to get into details, you can comfortably head to the 5 Most Used Prescription Drugs in the US. Prescription drugs have become an important part of healthcare in the US and around the […]
Business WireTeva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
TEL AVIV, Israel, May 09, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2022 Environmental, Social and Governance (ESG) Progress Report, which highlights the Company's achievements, such as completing more than 40% of its 23 long-term targets, including six ahead of schedule. The Company successfully met its 2030 target to increase energy efficiency, exceeded its 2030 target to reduce total water withdrawal in areas projected to be in water stress and met it
- Thomson Reuters StreetEvents
Q1 2023 Corcept Therapeutics Inc Earnings Call
Q1 2023 Corcept Therapeutics Inc Earnings Call
